Bluejay Diagnostics, Inc. (BJDX): Nasdaq/NYSE listing notice — Nasdaq grants Bluejay Diagnostics extension to Oct 23, 2023 to regain $1 bid price

Bluejay Diagnostics, Inc.

Company received original deficiency notice on Oct 25, 2022 for bid price below $1.
Nasdaq extended compliance deadline to Oct 23, 2023; must close at $1+ for 10 consecutive days.
Company may implement a reverse stock split, subject to stockholder approval, to regain compliance.
If not compliant by deadline, Nasdaq will delist the stock; appeal rights available.
No assurance of regaining or maintaining compliance with Nasdaq listing requirements.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Bluejay Diagnostics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

April 25, 2023, Nasdaq’s Listing Qualifications Staff notified the Company that it has extended the time period for the Company to regain compliance with the Minimum Bid Requirement until October 23, 2023. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 or higher for a minimum of ten consecutive business days. The Company intends to continue to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Requirement. Specifically, the Company has confirmed to Nasdaq that

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Bluejay Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-033248

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.